Skip to content
MarketScale
‹ Back to IndustriesHealthcare

What Should Building Managers Do If COVID Doesn’t Go Away?

We all want the coronavirus to go away and for COVID-19, social distancing and everything that goes with it to be remembered as a horrible part of a weird year. There are some encouraging signs, with Pfizer announcing promising news about a vaccine candidate and other medical companies making progress. But what if the…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share
What Should Building Managers Do If COVID Doesn’t Go Away?

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

We all want the coronavirus to go away and for COVID-19, social distancing and everything that goes with it to be remembered as a horrible part of a weird year.

There are some encouraging signs, with Pfizer announcing promising news about a vaccine candidate and other medical companies making progress. But what if the vaccine isn’t effective, the virus mutates or it returns in different forms, like the flu?

Those possibilities are why everyone, but especially building managers, must ask the question of what we do if COVID doesn’t go away, said John Shanahan, President of Ionogen.

“Maybe it’s a mutation or maybe the flu gets smarter. We have to have more long-term strategies for getting people back into business,” Shanahan said.

Shanahan has found his company’s hypochlorous solutions highly effective in Ionogen’s own office, with none of his team of 50 testing positive for COVID during the pandemic.

“In February, when this really started to ramp up, we deployed all the humidification devices in our building. Because we made surface sanitizers and disinfectants and they were still trying to figure out what COVID was, we put the air sanitizers up as a preventative measure,” he said. “We were so busy February, March, April and May that there was no stopping. But because we have both the physical staff in our manufacturing division and we needed to be able to collaborate, we just added more units into our space.”

Now, they’re looking into the positive results of hypochlorous actually getting into the upper respiratory areas and potentially killing the virus.

“We’re very excited about the future of where this is going to take us. We will continue, as always, to do more testing and trials and the continued research on this,” Shanahan said. “We’re committed to science, and we like proof. Anecdotes are great, and we’ve got a lot of anecdotes about how this has worked up until now. Now, we’ll continue to dig down into the science. Hypochlorous could very well be the antidote without having to take the immunization.”

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

ADA endorsement puts Weave on the shortlist for dental front-office tech

ADA endorsement puts Weave on the shortlist for dental front-office tech

Weave was named the exclusive patient engagement platform endorsed for American Dental Association members in March 2026. It lands as practices add more front-office systems. Weave’s Practice Analytics, launched in 2023, adds real-time metrics tied to Dentrix, Open Dental, and Eaglesoft.

  • 01Endorsements are becoming a procurement accelerant in dental tech: the ADA Member Advantage designation can move Weave into “default vendor” conversations when practices refresh phone, texting, reminders, and payments.
  • 02Analytics is moving from retrospective reporting to daily work queues: Weave’s Practice Analytics is positioned around unscheduled treatment plans, cancellations, and time-between-treatments, metrics that can be assigned to staff, not just reviewed by owners (according to Dental Products Report).
  • 03This matters most for groups standardizing across multiple sites: Business Wire frames Weave Enterprise as built to centralize operations across dozens or hundreds of locations, turning “patient communication” into a rollout and governance problem, not a single-office tool choice.

Sep 3, 2026

Radiology deal flow is splitting in two: $8B radiopharma and 14-state mobile imaging rollups

Radiology deal flow is splitting in two: $8B radiopharma and 14-state mobile imaging rollups

Radiology consolidation in 2026 is widening into two operationally different tracks: very large upstream radiopharma and imaging-component deals, and regional service platforms that bring imaging capacity to hospitals via mobile units and leased equipment. Radiology Business reported Curium signed a definitive agreement to acquire Lantheus for up to $8B after earlier reports put a potential deal near $7B, while Align Capital Partners agreed to buy Boise-based Heritage Imaging, a mobile diagnostic provider serving facilities across 14 states. For health systems, the immediate impact shows up less in headlines than in procurement and staffing: vendor portfolios can change quickly after component M&A, while outsourced and mobile imaging platforms change how rural and community facilities source PET-CT, MRI, and nuclear medicine capacity. Radiology Today’s management guidance on radiology mergers points to integration discipline, physician alignment, and process as the determinants of whether consolidation translates into measurable access and throughput improvements on the ground.

  • 01The same word, “consolidation,” now covers two very different buying problems: upstream supply and R&D bets (radiopharma, components) versus front-line capacity (mobile imaging and outsourced service lines).
  • 02Heritage Imaging’s 14-state footprint is a concrete benchmark for how far a mobile imaging platform can spread before standardization of protocols, credentialing, and PACS/RIS interfaces becomes the real work.
  • 03When deal values move from “reported” to “definitive” (as with Curium and Lantheus), procurement teams should assume faster portfolio and contracting changes, and pull forward vendor roadmap reviews tied to nuclear medicine and theranostics growth plans.

Sep 3, 2026

Direct-to-consumer telehealth raises spending, even as ASC investment surges

Direct-to-consumer telehealth raises spending, even as ASC investment surges

A Health Affairs analysis of commercial claims data (2011–13) found 12% of direct-to-consumer telehealth visits replaced visits to other providers and 88% represented new utilization, with net annual spending on acute respiratory illness increasing $45 per telehealth user. Separately, MobiHealthNews reported on August 31, 2026, via a HIMSSCast episode, that Erik Tellefson of Capital One said ambulatory surgery centers “represent one of the clearest growth structures in American healthcare.”

  • 01The most actionable benchmark for finance teams evaluating DTC telehealth is substitution rate, not visit growth. Health Affairs measured 12% substitution and 88% new utilization in commercial claims for acute respiratory illness.
  • 02The $45 per-user net annual spend increase in the Health Affairs analysis is small enough to hide in PMPM reporting but large enough to matter at scale, and it should be stress-tested against virtual-visit eligibility rules and repeat-use patterns.

Sep 2, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512